Influenza Caused by the Novel Influenza A (H1N1) Virus

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children

NCT00940108 | PHASE 2 | INTERVENTIONAL

The purpose of this study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy children.

5 Sites

370 Participants

Recruiting

6 Months to 8 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Study Site

Westmead,New South Wales,Australia,2145

Study Site

Brisbane,Queensland,Australia,4006

Study Site

North Adelaide,South Australia,Australia,5006

Study Site

Carlton,Victoria,Australia,3010

Study Site

Subiaco,Western Australia,Australia,6027

Study Eligibility Criteria

Inclusion Criteria

* Male or female aged \>= 6 months to \< 9 years at the time of the first study vaccination.
* For children \< 3 years of age at the time of first vaccination, born at or after 36 weeks of gestation.

Exclusion Criteria

* Known hypersensitivity to a previous dose of influenza virus vaccine or allergy to eggs, chicken protein, thiomersal, neomycin, polymyxin, or any components of the Study Vaccine.

Additional Studies

Additional studies can be found at ClinicalTrials.gov